CRISPR

$181.20
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$7.25 (-3.85%) Today

-$0.04 (-0.02%) As of 12:40 PM UTC after-hours

Why Robinhood?

You can buy or sell CRISPR and other stocks, options, and ETFs commission-free!

About CRSP

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland. The listed name for CRSP is CRISPR Therapeutics AG Common Shares.

CEO

Samarth Kulkarni

Employees

304

Headquarters

Zug, Zug

Founded

2014

Market Cap

13.49B

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

2.93M

High Today

$191.10

Low Today

$176.75

Open Price

$188.48

Volume

2.30M

52 Week High

$220.20

52 Week Low

$32.30

Collections

Analyst Ratings

53%

of 19 ratings

Buy

53%

Hold

37%

Sell

11%

CRSP Earnings

-$1.32

-$0.08

$1.16

$2.40

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Feb 10, Pre-Market